EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Contribution of Organic Anion Transporter 3 in Delayed Elimination of Methotrexate by Concomitant Administration of Febuxostat

Kenji Ikemura iD, Sakura Kobayashi, Danni Wang, Masahiro Okuda

Biopharmaceutics & Drug Disposition · 2025

DOI: 10.1002/bdd.70014 ↗

At a glance

Journal article in Biopharmaceutics & Drug Disposition, 2025. Written by Kenji Ikemura and 3 co-authors. Institution: Department of Pharmacy, The University of Osaka Hospital, Osaka, Japan. Major MEDLINE topics: Methotrexate, Febuxostat, Organic Anion Transporters, Sodium-Independent, Folic Acid Antagonists. 26 references. The full text is freely available (open access, CC BY 4.0). Funded by: Japan Research Foundation, Japan Foundation.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Methotrexate is an antifolate agent used for the treatment of various malignancies and is mainly secreted via human organic anion transporter 3 (hOAT3) in the proximal tubular cells. Coadministration of the xanthine oxidase inhibitor, febuxostat, in patients receiving methotrexate has been reported to be associated with an elevated risk of hematological toxicity and increased plasma methotrexate levels. Because febuxostat has an inhibitory effect against hOAT3, it may inhibit renal elimination of methotrexate via hOAT3. However, the drug interaction between methotrexate and febuxostat via hOAT3 remains to be clarified. In the present study, we investigated the effect of febuxostat on pharmacokinetics of methotrexate in rats and drug interaction between methotrexate and febuxostat using hOAT3‐expressing cultured cells. In the pharmacokinetics study using rats, concomitant administration of febuxostat significantly increased plasma concentration of methotrexate and prolonged its half‐life. In vitro studies showed that febuxostat inhibited hOAT3‐mediated transport of methotrexate in a concentration‐dependent manner. Dixon plot indicated that inhibitory constant value of febuxostat against methotrexate transport via hOAT3 was 0.63 ± 0.01 μM. Moreover, the inhibitory effect of febuxostat was of noncompetitive type. Taken together, these results suggest that concomitant administration of febuxostat delayed elimination of methotrexate, at least in part, by noncompetitive inhibition of hOAT3‐mediated methotrexate transport at clinical concentrations. The findings of this study provide novel information on drug interactions associated with febuxostat.

Subjects

MeSH terms (MEDLINE)

MethotrexateFebuxostatOrganic Anion Transporters, Sodium-IndependentFolic Acid AntagonistsAnimalsMaleHumansDrug InteractionsRats, Sprague-DawleyRatsHEK293 Cells

Author keywords

drug interactionfebuxostatmethotrexateorganic anion transporter 3

Substances

MethotrexateFebuxostatorganic anion transport protein 3Organic Anion Transporters, Sodium-IndependentFolic Acid Antagonists

Authors and institutions

  • Department of Pharmacy, The University of Osaka Hospital, Osaka, Japan.
  • Department of Hospital Pharmacy, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
  • Department of Hospital Pharmacy, School of Pharmaceutical Sciences, The University of Osaka, Osaka, Japan.

ORCID profiles: Kenji Ikemura

Funding

  • Japan Research Foundation
  • Japan Foundation

Cite

APA

Ikemura, K., Kobayashi, S., Wang, D., & Okuda, M. (2025). Contribution of Organic Anion Transporter 3 in Delayed Elimination of Methotrexate by Concomitant Administration of Febuxostat. Biopharmaceutics & Drug Disposition. https://doi.org/10.1002/bdd.70014

Vancouver

Ikemura K, Kobayashi S, Wang D, Okuda M. Contribution of Organic Anion Transporter 3 in Delayed Elimination of Methotrexate by Concomitant Administration of Febuxostat. Biopharmaceutics & Drug Disposition. 2025. doi:10.1002/bdd.70014

BibTeX
@article{Ikemura2025,
  author = {Ikemura, Kenji and Kobayashi, Sakura and Wang, Danni and Okuda, Masahiro},
  title = {Contribution of Organic Anion Transporter 3 in Delayed Elimination of Methotrexate by Concomitant Administration of Febuxostat},
  journal = {Biopharmaceutics & Drug Disposition},
  year = {2025},
  doi = {10.1002/bdd.70014}
}
Start for free →